SeekingAlpha · Aug 14, 2026
NeuroPace, Inc. (NPCE) Q2 2026 Earnings Call Transcript
NeuroPace, Inc. (NPCE) Q2 2026 Earnings Call August 11, 2026 4:30 PM EDTCompany ParticipantsScott Schaper - Head of Investor RelationsJoel Becker - CEO,...
NP
NASDAQ · NPCE
NeuroPace, Inc.
Healthcare · Medical - Devices
$14.03
Up+$0.01 (+0.07%)
Updated Aug 22, 2026, 11:02 PM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 548.85M
- P/E ratio
- -26.65
- Dividend yield
- 0.00%
- 52-week range
- $8.17 – $19.60
- Volume
- 115.98K
- Avg. volume
- 204.94K
Price performance
NPCE price history
1M range · 21 trading sessions · Daily adjusted prices
NPCE closed at $14.03 after 21 trading sessions, down 5.27% for the selected period.
- Last close
- $14.03
- Period change
- -5.27%
- Period low
- $12.89
- Period high
- $15.31
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $14.14 | $14.22 | $13.87 | $14.03 | 115.98K |
| Aug 20, 2026 | $14.35 | $14.60 | $13.56 | $14.02 | 191.8K |
| Aug 19, 2026 | $14.45 | $15.28 | $14.45 | $14.64 | 106.61K |
| Aug 18, 2026 | $14.27 | $14.645 | $14.03 | $14.47 | 140.67K |
| Aug 17, 2026 | $14.58 | $14.679 | $14.18 | $14.28 | 197.44K |
| Aug 14, 2026 | $14.46 | $14.80 | $14.29 | $14.77 | 154.96K |
| Aug 13, 2026 | $14.74 | $15.00 | $14.45 | $14.51 | 112.79K |
| Aug 12, 2026 | $14.16 | $15.23 | $14.16 | $14.56 | 186.27K |
| Aug 11, 2026 | $14.92 | $15.375 | $14.55 | $15.05 | 248.34K |
| Aug 10, 2026 | $14.68 | $15.00 | $14.45 | $14.88 | 234.54K |
| Aug 7, 2026 | $13.97 | $14.83 | $13.80 | $14.83 | 201.39K |
| Aug 6, 2026 | $13.67 | $14.37 | $13.62 | $13.90 | 286.86K |
| Aug 5, 2026 | $14.14 | $14.22 | $13.325 | $13.70 | 274.46K |
| Aug 4, 2026 | $13.65 | $14.27 | $13.57 | $14.14 | 275.09K |
| Aug 3, 2026 | $13.05 | $14.00 | $12.97 | $13.50 | 593.79K |
| Jul 31, 2026 | $13.74 | $13.74 | $12.66 | $12.89 | 332.03K |
| Jul 30, 2026 | $13.69 | $14.11 | $13.5101 | $13.75 | 229.17K |
| Jul 29, 2026 | $14.60 | $14.94 | $13.42 | $13.64 | 366.21K |
| Jul 28, 2026 | $15.53 | $15.83 | $15.20 | $15.31 | 154.72K |
| Jul 27, 2026 | $15.08 | $15.46 | $15.08 | $15.30 | 143.35K |
| Jul 24, 2026 | $14.87 | $15.00 | $14.28 | $14.81 | 268.93K |
Latest NPCE news
The latest Smart Investors Daily articles mentioning NPCE.
Stock researchCompany · Overview
NPCE research
Overview
Company profile and research snapshot.
Company profile
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $17.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 29, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 23, 2026 | Mizuho | Outperform | — |
| May 15, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 27, 2026 | HC Wainwright & Co. | Buy | — |
| Dec 16, 2025 | UBS | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 11, 2026
NeuroPace Raises FY2026 Sales Guidance from $99.000M-$101.000M to $99.500M-$101.500M vs $99.913M Est
NeuroPace (NASDAQ:NPCE) raises FY2026 sales outlook from $99.000 million-$101.000 million to $99.500 million-$101.500 million vs $99.913 million estimate.
Benzinga · Aug 11, 2026
NeuroPace Q2 EPS $(0.18) Beats $(0.20) Estimate, Sales $22.826M Beat $22.654M Estimate
NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.20) by 10 percent. This is a 30.77 percent increase over losses of $(0.26) per share from the same
Benzinga · Jul 29, 2026
HC Wainwright & Co. Reiterates Buy on NeuroPace, Maintains $20 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates NeuroPace (NASDAQ:NPCE) with a Buy and maintains $20 price target.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
